Cargando…

Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities

INTRODUCTION: Lung cancer screening criteria should select candidates with minimal cardiopulmonary comorbidities who are fit for curative lung cancer resection. METHODS: We retrospectively analyzed 728 patients with lung cancer for screening eligibility using the U.S. Preventive Services Task Force...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Chan Yeu, Lusk, Christine M., Neslund-Dudas, Christine, Gadgeel, Shirish, Soubani, Ayman O., Schwartz, Ann G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307937/
https://www.ncbi.nlm.nih.gov/pubmed/35880085
http://dx.doi.org/10.1016/j.jtocrr.2022.100377
_version_ 1784752874218061824
author Pu, Chan Yeu
Lusk, Christine M.
Neslund-Dudas, Christine
Gadgeel, Shirish
Soubani, Ayman O.
Schwartz, Ann G.
author_facet Pu, Chan Yeu
Lusk, Christine M.
Neslund-Dudas, Christine
Gadgeel, Shirish
Soubani, Ayman O.
Schwartz, Ann G.
author_sort Pu, Chan Yeu
collection PubMed
description INTRODUCTION: Lung cancer screening criteria should select candidates with minimal cardiopulmonary comorbidities who are fit for curative lung cancer resection. METHODS: We retrospectively analyzed 728 patients with lung cancer for screening eligibility using the U.S. Preventive Services Task Force (USPSTF) 2013 criteria (n = 370). If ineligible for screening, they were further assessed for eligibility using the USPSTF 2021 (n = 121) and National Comprehensive Cancer Network group 2 (NCCN gp 2) (n = 155). Comparisons of cardiopulmonary comorbidities between patients selected by the different lung cancer screening criteria were performed. Excluding missing data, a similar comparison was done between USPSTF 2013 (n = 283) and PLCOm2012 (risk threshold ≥1.51%) (n = 118). RESULTS: Patients eligible for USPSTF 2021 and NCCN gp 2 had lower rates of airflow obstruction (forced expiratory volume in 1 s [FEV1]/forced vital capacity <0.7) compared with those in USPSTF 2013 (55.4% and 56.8% versus 70.5%). Both USPSTF 2021 and NCCN gp 2 groups had less severe airflow obstruction; only 11.6% and 12.9% of patients, respectively, had percent-predicted FEV1 less than 50% versus 20.3% in the USPSTF 2013 group. Comparing USPSTF 2013 and PLCOm2012 revealed no significant differences in age or the rate of airflow obstruction (p = 0.06 and p = 0.09 respectively). Nevertheless, rates of percent-predicted FEV1 less than 50% and diffusing capacity of the lungs for carbon monoxide less than 50% were lower in the PLCOm2012 group compared with those in the USPSTF 2013 group (22.3% versus 10.2% and 32.6% versus 20.0%), respectively. CONCLUSIONS: The USPSTF 2021 qualifies an additional group of screening candidates who are healthier with better lung reserve, translating to better surgical candidacy but potentially more overdiagnosis. The PLCOm2012, with its better accuracy in selecting patients at risk of cancer, selects an older group with chronic obstructive pulmonary disease but with good lung reserve and potentially less overdiagnosis.
format Online
Article
Text
id pubmed-9307937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93079372022-07-24 Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities Pu, Chan Yeu Lusk, Christine M. Neslund-Dudas, Christine Gadgeel, Shirish Soubani, Ayman O. Schwartz, Ann G. JTO Clin Res Rep Original Article INTRODUCTION: Lung cancer screening criteria should select candidates with minimal cardiopulmonary comorbidities who are fit for curative lung cancer resection. METHODS: We retrospectively analyzed 728 patients with lung cancer for screening eligibility using the U.S. Preventive Services Task Force (USPSTF) 2013 criteria (n = 370). If ineligible for screening, they were further assessed for eligibility using the USPSTF 2021 (n = 121) and National Comprehensive Cancer Network group 2 (NCCN gp 2) (n = 155). Comparisons of cardiopulmonary comorbidities between patients selected by the different lung cancer screening criteria were performed. Excluding missing data, a similar comparison was done between USPSTF 2013 (n = 283) and PLCOm2012 (risk threshold ≥1.51%) (n = 118). RESULTS: Patients eligible for USPSTF 2021 and NCCN gp 2 had lower rates of airflow obstruction (forced expiratory volume in 1 s [FEV1]/forced vital capacity <0.7) compared with those in USPSTF 2013 (55.4% and 56.8% versus 70.5%). Both USPSTF 2021 and NCCN gp 2 groups had less severe airflow obstruction; only 11.6% and 12.9% of patients, respectively, had percent-predicted FEV1 less than 50% versus 20.3% in the USPSTF 2013 group. Comparing USPSTF 2013 and PLCOm2012 revealed no significant differences in age or the rate of airflow obstruction (p = 0.06 and p = 0.09 respectively). Nevertheless, rates of percent-predicted FEV1 less than 50% and diffusing capacity of the lungs for carbon monoxide less than 50% were lower in the PLCOm2012 group compared with those in the USPSTF 2013 group (22.3% versus 10.2% and 32.6% versus 20.0%), respectively. CONCLUSIONS: The USPSTF 2021 qualifies an additional group of screening candidates who are healthier with better lung reserve, translating to better surgical candidacy but potentially more overdiagnosis. The PLCOm2012, with its better accuracy in selecting patients at risk of cancer, selects an older group with chronic obstructive pulmonary disease but with good lung reserve and potentially less overdiagnosis. Elsevier 2022-07-04 /pmc/articles/PMC9307937/ /pubmed/35880085 http://dx.doi.org/10.1016/j.jtocrr.2022.100377 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Pu, Chan Yeu
Lusk, Christine M.
Neslund-Dudas, Christine
Gadgeel, Shirish
Soubani, Ayman O.
Schwartz, Ann G.
Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title_full Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title_fullStr Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title_full_unstemmed Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title_short Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities
title_sort lung cancer screening criteria and cardiopulmonary comorbidities
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307937/
https://www.ncbi.nlm.nih.gov/pubmed/35880085
http://dx.doi.org/10.1016/j.jtocrr.2022.100377
work_keys_str_mv AT puchanyeu lungcancerscreeningcriteriaandcardiopulmonarycomorbidities
AT luskchristinem lungcancerscreeningcriteriaandcardiopulmonarycomorbidities
AT neslunddudaschristine lungcancerscreeningcriteriaandcardiopulmonarycomorbidities
AT gadgeelshirish lungcancerscreeningcriteriaandcardiopulmonarycomorbidities
AT soubaniaymano lungcancerscreeningcriteriaandcardiopulmonarycomorbidities
AT schwartzanng lungcancerscreeningcriteriaandcardiopulmonarycomorbidities